Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Rocha, Milagros ^a,b,c,d   Bañuls, Celia ^a,c,d   Bellod, Lorena ^a,b,d   Rovira Llopis, Susana ^a,b   Morillas, Carlos ^a,b,c,d   Solá, Eva ^a,b,c,d   Víctor, Víctor M ^a,b,c,d   Hernández Mijares, Antonio ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; LOWER LARGE HIGH DENSITY LIPOPROTEIN; RETINOL BINDING PROTEIN 4; SMALL AND DENSE LOW DENSITY LIPOPROTEIN; SMALL HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PROTEIN BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, MORBID; RETINOL-BINDING PROTEINS, PLASMA; TRIGLYCERIDES;

EID: 84892412665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078670     Document Type: Article

References (46)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. (2010) Heart disease and stroke statistics (a report from the American Heart Association). Circulation 121: 46-215.
2. Glass CK, Witztum JL (2001) Atherosclerosis:The road ahead. Cell 104: 503-516.
3. Musunuru K (2010) Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 45: 907-914.
4. Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL -guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3: 144-153.
5. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362.
6. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563.
7. Gavi S, Stuart LM, Kelly P, Melendez MM, Mynarcik DC, et al. (2007) Retinolbinding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 92: 1886-1890.
8. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, et al. (2007) High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30: 1173-1178.
9. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, et al. (2006) Retinolbinding protein 4 in human obesity. Diabetes 55: 2805-2810.
10. Ulgen F, Herder C, Kühn MC, Willenberg HS, Schott M, et al. (2010) Association of serum levels of retinol-binding protein 4 with male sex but not with insulin resistance in obese patients. Arch Physiol Biochem 116: 57-62.
11. Promintzer M, Krebs M, Todoric J, Luger A, Bischof MG, et al. (2007) Insulin resistance is unrelated to circulating retinol binding protein and protein C inhibitor. J Clin Endocrinol Metab 92: 4306-4312.
12. von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, et al. (2007) Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 50: 1930-1937.
13. Qi Q, Yu Z, Ye X, Zhao F, Huang P, et al. (2007) Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 92: 4827-4834.
14. Vergès B, Guiu B, Cercueil JP, Duvillard L, Robin I, et al. (2012) Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein b100 catabolism in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 32: 3050-3057.
15. Makino S, Fujiwara M, Suzukawa K, Handa H, Fujie T, et al. (2009) Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. Horm Metab Res 41: 221-226.
16. Takashima N, Tomoike H, Iwai N (2006) Retinol-binding protein 4 and insulin resistance. N Engl J Med 355: 1392.
17. Wu J, Shi YH, Niu DM, Li HQ, Zhang CN, et al. (2012) Association among retinol-binding protein 4, small dense LDL cholesterol and oxidized LDL levels in dyslipidemia subjects. Clin Biochem 45: 619-622.
18. Usui S, Ichimura M, Ikeda S, Okamoto M (2009) Association between serum retinol-binding protein 4 and small dense low-density lipoprotein cholesterol levels in young adult women. Clin Chim Acta 399: 45-48.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
20. American Diabetes Association (2012) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 35: S64-S71.
21. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, et al. (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47: 266-274.
22. Cho YM, Youn BS, Lee H, Lee N, Min SS, et al. (2006) Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29: 2457-2461.
23. Jia W, Wu H, Bao Y, Wang C, Lu J, et al. (2007) Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 92: 3224-3229.
24. Saad MF, Damani S, Gingerich RL, Riad-Gabriel MG, Khan A, et al. (1997) Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 82: 579-584.
25. Alkharfy KM, Al-Daghri NM, Vanhoutte PM, Krishnaswamy S, Xu A (2012) Serum retinol-binding protein 4 as a marker for cardiovascular disease in women. PLoS ONE 7: e48612.
26. Chiba M, Saitoh S, Ohnishi H, Akasaka H, Mitsumata K, et al. (2010) Associations of metabolic factors, especially serum retinol-binding protein 4 (RBP4), with blood pressure in Japanese -the Tanno and Sobetsu study. Endocr J 57: 811-817.
27. Lin CJ, Chu NF, Hung YJ, Chang JB, He CT, et al. (2013) The association of retinol-binding protein 4 with metabolic syndrome and obesity in adolescents: the effects of gender and sex hormones. Pediatr (Phila) 52: 16-23.
28. Hermsdorff HH, Zulet MA, Puchau B, Martínez JA (2011) Central adiposity rather than total adiposity measurements are specifically involved in the inflammatory status from healthy young adults. Inflammation 34: 161-170.
29. Yu Z, Sun L, Qi Q, Wu H, Lu L, et al. (2012) Hypertriglyceridemic waist, cytokines and hyperglycaemia in Chinese. Eur J Clin Invest 42: 1100-1111.
30. Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, et al. (2007) Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6: 79-87.
31. Lee JW, Im JA, Lee HR, Shim JY, Youn BS, et al. (2007) Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring) 15: 2225-2232.
32. Lim S, Yoon JW, Choi SH, Park YJ, Lee JJ, et al. (2010) Combined impact of adiponectin and retinol-binding protein 4 on metabolic syndrome in elderly people: the Korean Longitudinal Study on Health and Aging. Obesity (Silver Spring) 18: 826-832.
33. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007) Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 92: 2712-2719.
34. Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, et al. (2010) The APOA5-1131 T.C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis 20: 243-248.
35. Staels B (2001) Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol 45: S158-S167.
36. Koba S, Yokota Y, Hirano T, Ito Y, Ban Y, et al. (2008) Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb 15: 250-260.
37. Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, et al. (2007) Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 108: 282-289.
38. Packard CJ (2006) Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17: 412-417.
39. Packard CJ (2003) Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31: 1066-1069.
40. Klop B, Elte JW, Cabezas MC (2013) Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 5: 1218-1240.
41. Smith JD (2010) Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol 4: 382-388.
42. van der Westhuyzen DR, de Beer FC, Webb NR (2007) HDL cholesterol transport during inflammation. Curr Opin Lipidol 18: 147-151.
43. Farjo KM, Farjo RA, Halsey S, Moiseyev G, Ma JX (2012) Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase- and nuclear factor kappa B-dependent and retinol-independent mechanism. Mol Cell Biol 32: 5103-5115.
44. Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, et al. (2008) The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience 2:67.
45. Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, et al. (1999) Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat 57: 277-283.
46. Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, et al. (2008) Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 68: 9512-9518.